Bayer’s Chinese Filing and Supreme Court Tailwind Set the Stage for a Pivotal Earnings Season

Bayer seeks China approval for Kerendia in non-diabetic CKD, as Supreme Court ruling cuts Roundup liability and $5B bond issuance bolsters finances.

Bayer has submitted a regulatory application in China for a new indication of its kidney drug Kerendia (finerenone), targeting chronic kidney disease in non-diabetic patients. The move, announced Thursday, follows the drug’s approval for heart failure in the country back in May and is designed to broaden the medicine’s commercial reach in one of the world’s largest healthcare markets. Kerendia is a key growth asset in Bayer’s pharmaceuticals division, which has been grappling with patent expirations on older blockbusters.

The filing arrives as the German conglomerate barrels toward a packed August calendar. On Tuesday, August 4, Bayer will publish its half-year financial report, followed by a media update on the business outlook. Two weeks later, on August 19, a Missouri court will hold the fairness hearing for the proposed $7.25 billion settlement of Roundup-related glyphosate lawsuits — a date that has already been pushed back from an earlier slot. Then on September 2, the Crop Science division will host an investor event.

The legal landscape has shifted decisively in Bayer’s favor in recent weeks. On June 25, the U.S. Supreme Court ruled 7-2 in the “Durnell” case that federal law preempts state-level claims over inadequate cancer warnings on glyphosate products. Chief Executive Bill Anderson called the decision “overdue clarity” for the entire industry, according to Reuters. The ruling significantly reduces Bayer’s future liability exposure in the Roundup litigation, though the settlement still requires final court approval.

Adding a twist to the legal narrative, Bayer withdrew its petition for antidumping tariffs on Chinese glyphosate imports in late June, bowing to pressure from U.S. farm groups concerned about rising herbicide costs for growers. That reversal, while tactical, could factor into how analysts assess the overall risk profile of the agricultural business.

On the financing front, Bayer US Finance LLC placed $5.0 billion in U.S. dollar-denominated bonds in mid-July, guaranteed by the parent company. The proceeds are earmarked for balance sheet support and refinancing, giving Bayer additional financial flexibility as it continues to manage legal contingencies. The debt issuance comes as new Chief Financial Officer Judith Hartmann, who officially took the reins in early June, focuses on deleveraging and optimizing the capital structure.

Operationally, Bayer is pushing ahead with structural changes. On Wednesday, the company announced the creation of a standalone, wholly owned operating company for its Bergkamen site, which is slated to begin operations in 2027. The subsidiary will concentrate on infrastructure and site services. In the agricultural segment, Bayer secured a licensing agreement with French plant breeder RAGT to co-develop hybrid wheat for Europe and North America, with a market launch targeted for the early 2030s.

First-quarter results, released in May, showed revenue slipping 2.4% to €13.41 billion, but earnings per share more than doubled to €2.81 from €1.32 a year earlier. The half-year report will test whether that earnings momentum has been sustained.

Analyst sentiment remains broadly positive. JPMorgan Chase reiterated its “Overweight” rating with a €50 price target, citing the Supreme Court ruling as a fundamental de-risking event. UBS analyst Matthew Weston assigned a “Buy” rating and a €52 target, while Barclays also reaffirmed a buy recommendation.

The stock has responded to the improving news flow. Bayer shares traded at €48.16 on Thursday, up 1.47% on the day, bringing the week’s gain to 4.31% and the year-to-date advance to 30.13%. That still leaves the stock roughly 10% below its 52-week high of €53.86, reached in early July. With the half-year numbers, the glyphosate settlement hearing, and the Crop Science investor day all looming, volatility is likely to remain elevated in the weeks ahead.